PubMed Health⌕ Search

PubMed · 3072193

Compliant populations: variability in serum concentrations.

Abstract

Safety and efficacy studies of new antiepileptic drugs require strict adherence to prescribed dosage regimens. Therefore, they provide a unique opportunity to investigate the variability in serum concentrations that are seen in a compliant group of motivated patients. Phenytoin and carbamazepine serum concentrations from two safety and efficacy trials were evaluated for coefficient of variation, difference from baseline concentration, and percent difference. Coefficient of variation for phenytoin was usually less than 20% and was not influenced by baseline serum concentration or frequency of administration. There was no relationship between serum concentration and frequency of administration on carbamazepine coefficient of variation which was less than 25% in most cases. Most PHT differences from baseline were within 5 micrograms/ml, whereas most CBZ differences were within 2 micrograms/ml. Most PHT concentrations were within 30% of each other whereas most CBZ concentrations were within 40% of each other. Data from this study provide information regarding the variability of phenytoin and carbamazepine concentrations under ideal conditions and can be used to set limits for fluctuations of concomitant antiepileptic drugs in safety and efficacy trials or ideal patient care settings.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

N M Graves, G B Holmes, I E Leppik. 1988. Compliant populations: variability in serum concentrations.. https://pubmed.ncbi.nlm.nih.gov/3072193/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double-blind placebo-controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 +/- 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn-Tolosa-Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI-C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 +/- 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (-0.50 +/- 0.72 vs. 0.30 +/- 0.79 m/s(2); P = 0.03). On the CGI-C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was "minimally improved." Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry.

Anticonvulsants↗